Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer... Oct 24
Galera Therapeutics announces dosing of first patient in the phase 1/2 GRECO-1 clinical trial of GC4711 in combination with SBRT for non-small ... Oct 23
-Advertisements-